503612-45-1

Basic information

• Product Name: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile
• Synonyms: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile
• CAS NO: 503612-45-1
• Molecular Weight: 441.489
• Mol File: 503612-45-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile(503612-45-1)
• EPA Substance Registry System: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonitrile(503612-45-1)

Safety Data

• Hazardous Substances Data: 503612-45-1(Hazardous Substances Data)

Usage

Chemical class

Complex organic compound

Structural arrangement

Unique, consisting of a pyrazolopyridine core with a carbonitrile group and various substituted phenyl rings

Substituents

Methoxy, oxo, and piperidinyl groups

Chemical complexity

Enhanced by the presence of these substituents

Potential applications

Pharmaceutical research and development due to its intricate structure and potential for diverse biological activities

Current understanding

Limited, requiring further studies to fully understand and harness its potential applications
Please note that this list is based on the provided material and may not be exhaustive. Further research and analysis may reveal additional properties and specific content related to this compound.

Upstream product

• 473927-63-8 ethyl (2Z)-chloro[2-(4-methoxyphenyl)hydrazinylidene]ethanoate 
• 53106-58-4 (4-methoxyphenyl)carbonocyanidohydrazonic chloride 
• 27471-37-0 (2-oxopiperidine-1-yl)chlorobenzene 
• 27471-36-9 5-chloro-N-(4-chlorophenyl)pentanamide 
• 106-47-8 4-chloro-aniline 
• 41419-12-9 3,3-dichloro-piperidin-2-one 
• 27143-07-3 ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate 
• 536760-29-9 3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one 
• 473927-65-0 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide 
• 675-20-7 piperidin-2-one 
• 881386-01-2 3,3-dichloro-1-(4-nitrophenyl)piperidine-2-one 
• 503614-91-3 1-(4-methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester 
• 38560-30-4 1-(4-nitrophenyl)piperidine-2-one 
• 1421823-20-2 ethyl 6-(4-(N-(4-chlorobutyl)carboxamido)phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate 

Downstream Products

• 503612-86-0 1-(4-methoxyphenyl)-3-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-6-(4-(2-oxopiperidin-1-yl)phenyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one 

Relevant articles and documents

Preparation method of apixaban and intermediate thereof

The invention relates to a preparation method of apixaban (an antithrombotic drug) and a related intermediate, The preparation method comprises the specific steps as follows: carrying out amidation-cyclization integrated reaction on p-nitroaniline, which

Apixaban derivatives as well as preparation method and application thereof

The invention belongs to the technical field of medicines and discloses apixaban derivatives and analogues as well as a preparation method and application thereof. The structure of the compounds is shown as the following formula. Cheap and readily available paranitroaniline serves as an initial raw material. The preparation method comprises the following steps: performing amidation-cyclization, chlorination, condensation-elimination, cyclization-elimination, reduction, amidation-cyclization so as to obtain a key intermediate; and dehydrating, performing ammonolysis or chlorination, and condensing to synthesize the target compound. The method is simple in operation, convenient in after-treatment and high in yield. The in-vitro anti-coagulant activity of the target compound is investigated by determining the activated partial thromboplastin time (APTT) and thromboplastin time (PT). The EC2X(APTT) of result compounds APX-02, APX-15 and APX-16 is respectively 2.15mug/L, 3.65mug/L and 2.35mug/L, the EC2X(PT) of the result compounds is respectively 0.12mug/L, 3.57mug/L and 1.57mug/L, which are higher than the EC2X(APTT) value of 3.78mug/L and the EC2X(PT) value of 1.59mug/L of a positive control agent Apixaban. The compounds have high anti-coagulant activities. The EC2X(APTT) value of the rest compounds is between 5mug/L and 65mug/L, and the EC2X(PT) value is between 3mug/L and 18mug/L. The structural formula is as shown in the specification.

LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.